Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
J. Clin. Oncol 2020 Jun 02;[EPub Ahead of Print], DA Palma, R Olson, S Harrow, S Gaede, AV Louie, C Haasbeek, L Mulroy, M Lock, GB Rodrigues, BP Yaremko, D Schellenberg, B Ahmad, S Senthi, A Swaminath, N Kopek, M Liu, K Moore, S Currie, R Schlijper, GS Bauman, J Laba, XM Qu, A Warner, S SenanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.